真性红细胞增多症的治疗选择。
The choice of treatment in polycythaemia vera.
作者信息
Najean Y, Dresch C
出版信息
Drugs Exp Clin Res. 1986;12(1-3):177-80.
PMID:3525073
Abstract
The current results of prospective protocols initiated by the Polycythaemia Vera Study Group are presented. These results help to define the best choice of treatment in accordance with the risk factors.
摘要
本文展示了真性红细胞增多症研究组启动的前瞻性方案的当前结果。这些结果有助于根据风险因素确定最佳治疗选择。
相似文献
1
The choice of treatment in polycythaemia vera.真性红细胞增多症的治疗选择。
Drugs Exp Clin Res. 1986;12(1-3):177-80.
2
Treatment of polycythaemia vera.
Clin Haematol. 1975 Jun;4(2):441-56.
3
Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols.基于真性红细胞增多症研究组方案的真性红细胞增多症治疗建议。
Semin Hematol. 1986 Apr;23(2):132-43.
4
Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy.与苯丁酸氮芥治疗相关的真性红细胞增多症患者急性白血病发病率增加。
N Engl J Med. 1981 Feb 19;304(8):441-7. doi: 10.1056/NEJM198102193040801.
5
Maintenance therapy of 32P-induced remission in polycythemia vera. A clinical trial of chlorambucil and hydroxy-urea in 109 cases.真性红细胞增多症中32P诱导缓解后的维持治疗。苯丁酸氮芥和羟基脲治疗109例的临床试验。
Nouv Rev Fr Hematol (1978). 1978 Nov 25;20(3):377-85.
6
[Efficacious treatment of a fatal blood disease: polycythemia vera].[一种致命血液疾病——真性红细胞增多症的有效治疗方法]
Sangre (Barc). 1997 Jun;42(3):215-8.
7
Acute leukemia in polycythemia vera.真性红细胞增多症中的急性白血病
Semin Hematol. 1986 Apr;23(2):156-65.
8
Busulfan versus 32P in polycythaemia vera.
Drugs Exp Clin Res. 1986;12(1-3):283-5.
9
Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.真性红细胞增多症、原发性血小板增多症和骨髓纤维化伴髓样化生患者接受羟基脲治疗的白血病发生风险。
Am J Hematol. 1996 May;52(1):42-6. doi: 10.1002/(SICI)1096-8652(199605)52:1<42::AID-AJH7>3.0.CO;2-6.
10
Neurologic complications of polycythemia and their impact on therapy.真性红细胞增多症的神经系统并发症及其对治疗的影响。
Oncology (Williston Park). 1990 Mar;4(3):59-64; discussion 64-6.
Zotero 插件